In 2019, the Food and Drug Administration (FDA) approved brexanolone, marketed by Sage Therapeutics as Zulresso, as a treatment for postpartum depression (PPD). As a neurosteroid, brexanolone represents a novel approach to the treatment of postpartum mood disorders. One of the most exciting things about brexanolone is the rapidity of the response, with the initial… Read More »
Postpartum psychosis (PPP) is a rare but serious psychiatric illness, occurring in 1 to 2 per 1000 women in the weeks. Because postpartum psychosis is so rare, we do not have specific guidelines regarding its treatment. While the last decade has brought increased awareness of the prevalence and treatment of postpartum depression, our knowledge… Read More »
Because postpartum psychosis is a relatively rare event, we do not have as much information on this illness as we have on postpartum depression. In addition, most of the literature we have on postpartum psychosis is not new. A few years back, the American Journal of Psychiatry published an excellent review. Another useful resource was… Read More »
FDA Approves Zulresso (brexanolone) for the Treatment of Postpartum Depression Print this page March 19, 2019 — The U.S. Food and Drug Administration today approved Zulresso (brexanolone) injection for intravenous (IV) use for the treatment of postpartum depression (PPD) in adult women. This is the first drug approved by the FDA specifically for PPD. “Postpartum depression… Read More »
The first drug for women suffering postpartum depression received federal approval on Tuesday, a move likely to pave the way for a wave of treatments to address a debilitating condition that is the most common complication of pregnancy. The drug works very quickly, within 48 hours — a significant improvement over currently available antidepressants, which… Read More »
January 30, 2019 from ObGynNews The last decade has brought appropriate attention to the high prevalence of postpartum mood and anxiety disorders, with postpartum depression (PPD) constituting the most common complication in modern obstetrics. There have been very substantial efforts in more than 40 states in the United States to enhance screening for PPD and… Read More »